Press Releases/News

June 28, 2021

Pinteon Therapeutics Encouraged by Publication of Preclinical Study Supporting PNT001 for the Treatment of Tauopathies in Science Translational Medicine

June 24, 2021

Pinteon Extends Collaboration with Lonza for Manufacturing PNT001, a Novel Tau Antibody Targeting Alzheimer’s Disease and Traumatic Brain Injury

June 17, 2021

Pinteon Therapeutics Announces $3 Million Award from Advanced Technology International to Support Phase 1 Study of PNT001 in Patients with Acute Traumatic Brain Injury

April 6, 2021

Pinteon Therapeutics Announces First Patient Dosed in Phase 1 Study of PNT001 in Patients with Acute Traumatic Brain Injury

February 1, 2021

Pinteon Therapeutics Announces Promising Phase 1 Data for Novel Tau Antibody PNT001

January 28, 2021

Pinteon Therapeutics Announces Upcoming Scientific Presentations

June 28, 2021

Pinteon Therapeutics Encouraged by Publication of Preclinical Study Supporting PNT001 for the Treatment of Tauopathies in Science Translational Medicine

June 24, 2021

Pinteon Extends Collaboration with Lonza for Manufacturing PNT001, a Novel Tau Antibody Targeting Alzheimer’s Disease and Traumatic Brain Injury

June 17, 2021

Pinteon Therapeutics Announces $3 Million Award from Advanced Technology International to Support Phase 1 Study of PNT001 in Patients with Acute Traumatic Brain Injury

April 6, 2021

Pinteon Therapeutics Announces First Patient Dosed in Phase 1 Study of PNT001 in Patients with Acute Traumatic Brain Injury

February 1, 2021

Pinteon Therapeutics Announces Promising Phase 1 Data for Novel Tau Antibody PNT001

January 28, 2021

Pinteon Therapeutics Announces Upcoming Scientific Presentations

May 6, 2020

Pinteon Therapeutics Announces Scientific Advisory Board for Traumatic Brain Injury

October 31, 2019

Pinteon Therapeutics Launches Phase 1 Trial of Novel Tau Antibody that Targets a Potent Driver of Neurodegenerative Disease